Ligand Pharmaceuticals (LGND) EPS (Diluted) Growth (3y) (2013 - 2026)
Ligand Pharmaceuticals (LGND) EPS (Diluted) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 78.99% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 37.28% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.39% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -2.00% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 83.94% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn | -93.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -93.50% |
| Dec 31, 2025 | 144.49% |
| Sep 30, 2025 | 132.32% |
| Jun 30, 2025 | 32.08% |
| Mar 31, 2025 | -147.46% |
| Dec 31, 2024 | -136.25% |
| Mar 31, 2023 | 60.11% |
| Dec 31, 2022 | 22.29% |
| Sep 30, 2022 | 12.76% |
| Jun 30, 2022 | -2.76% |
| Mar 31, 2022 | -26.09% |
| Dec 31, 2021 | 58.20% |
| Sep 30, 2021 | -28.82% |
| Jun 30, 2021 | -28.29% |
| Mar 31, 2021 | -29.03% |
| Mar 31, 2019 | 749.35% |
| Dec 31, 2018 | -99.23% |
| Sep 30, 2018 | -32.93% |
| Mar 31, 2016 | 75.73% |
| Jun 30, 2013 | 731.66% |